MedTrace Logo

Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis

NCT06779136 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2025-04-18

No results posted yet for this study

Summary

A phase III clinical study to evaluate the efficacy and safety of a humanized MG-K10 mab injection in subjects with prurigo nodularis.administered every 4 weeks for 56 weeks.

Conditions

  • Prurigo Nodularis

Interventions

DRUG

Placebo

Every four weeks, subcutaneous injection，Switch to MG-K10 treatment after 24 weeks of administration

Sponsors & Collaborators

  • Shanghai Mabgeek Biotech.Co.Ltd

    lead OTHER_GOV

Principal Investigators

  • Jianzhong Zhang, Medical Ph.D · Feking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-26
Primary Completion
2026-08-31
Completion
2026-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06779136 on ClinicalTrials.gov